SELLAS Life Sciences Group, Inc.
Announce clinical activity for the lymphoma group
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Aug 2023
- Due
- 30 Sep 2023
- Delivered
- September 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Observed clinical activity in the lymphoma group will be announced after the last dose level is complete and is expected during the third quarter of 2023.”
What we found
Evidence strength A What the grades mean
The company announced positive topline data for the relapsed/refractory lymphoma patient group in September 2023, meeting the commitment to report clinical activity during the third quarter of 2023.
-
A SELLAS Life Sciences Group, Inc. 10-Q filed 2023-11-09
“In September 2023, we announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from the Phase 1 dose-escalation trial of SLS009 as well as the RP2D of 100 mg for this patient population.” ✓ confirmed on the page
Market reaction: the shares moved -7.1% against the S&P 500 over the three sessions around the disclosure (8 Nov 2023 to 13 Nov 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Announce
- Deliverable
- Clinical activity data for lymphoma group
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002022 · Corrections policy